Hanimune Therapeutics

Executive Summary

Hanimune Therapeutics is a San Diego-based private company founded in 2022 that aims to revolutionize food allergy management through simple, food-based solutions. Leveraging deep expertise in food function, sourcing, and processing, the company develops products designed to support tolerance development to common allergens. Its strategy centers on early and consistent introduction of allergens, primarily targeting infants but also applicable to individuals of any age with food allergies. By focusing on a preventive approach rather than treatment after sensitization, Hanimune addresses a large and growing market of parents seeking safer ways to introduce allergens to their children. The company is still in early stages, with limited public information on funding or partnerships, but its approach aligns with current medical guidelines recommending early allergen introduction. Success will depend on demonstrating safety and efficacy in clinical settings, navigating regulatory pathways for food-based interventions, and establishing manufacturing and distribution partnerships.

Upcoming Catalysts (preview)

• H2 2026Initiation of a clinical study for infant allergen introduction product60% success
• Q4 2026FDA meeting or guidance on regulatory classification of food-based allergen product70% success
• Q1 2027Strategic partnership with a pediatric nutrition or infant food company50% success